This article is more than 5 years old. Information may no longer be current.
J.P. Reilly, MD, on the ZEUS trial
Click Here to Manage Email Alerts
WASHINGTON — In this video, J.P. Reilly, MD, interventional cardiologist at Ochsner Medical Center in New Orleans, discusses the results from the ZEUS trial, presented at the American College of Cardiology Scientific Sessions.
The researchers randomly assigned 1,600 patients with normal or increased bleeding or thrombotic risk to receive either an Endeavor zotarolimus-eluting stent (Medtronic) or a bare-metal stent, along with dual antiplatelet therapy. Patients at normal or high risk for bleeding received 1 month of treatment, while those at a high thrombotic risk received therapy tailored to their needs, typically with a duration between 6 and 12 months.
The results indicated a higher risk for MI and MACE in the BMS group compared with the drug-eluting stent. Patients who received an Endeavor stent had half the risk for stent thrombosis and a 5% risk reduction for MACE, Reilly said.
He concluded that these results suggest that the Endeavor stent allows for a 1-month duration of dual antiplatelet therapy as opposed to the typically prescribed 6 or 12 months for patients with DES. Corroboration of these results, Reilly added, would benefit patients at high risk for bleeding, as well as those who require surgery after stenting.